Stock Earnings

Question 1

What are CRISPR Therapeutics AG's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), CRISPR Therapeutics AG has a total asset of $2,265, Net loss of $-581

Question 2

What are the key financial ratios for CRSP?

Accepted Answer

CRISPR Therapeutics AG's Current ratio is 6.6, has a Net margin is -19,366.66, sales per share of $0.03.

Question 3

How is CRISPR Therapeutics AG's revenue broken down by segment or geography?

Accepted Answer

CRISPR Therapeutics AG largest revenue segment is Genome-editing Technology, at a revenue of 3,510,000 in the most earnings release.For geography, Switzerland and United States is the primary market for CRISPR Therapeutics AG, at a revenue of 3,510,000.

Question 4

Is CRISPR Therapeutics AG profitable?

Accepted Answer

no, according to the latest financial statements, CRISPR Therapeutics AG has a net loss of $-581

Question 5

Does CRISPR Therapeutics AG have any liabilities?

Accepted Answer

yes, CRISPR Therapeutics AG has liability of 343

Question 6

How many outstanding shares for CRISPR Therapeutics AG?

Accepted Answer

CRISPR Therapeutics AG has a total outstanding shares of 95.89

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	4	3	37	371	1	915
Revenue Growth (YoY)	-89%	-92%	-90%	37,000%	-100%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	273	287	183	206	212	102
Research & Development	280	284	320	387	461	438
Operating Expenses	650	571	503	593	674	541
Other Non Operating Income (Expenses)	81	86	103	71	22	6
Pretax Income	-565	-577	-362	-150	-650	379
Income Tax Expense	3	3	3	2	0	1
Net Income	-568	-581	-366	-153	-650	377
Net Income Growth	48%	59%	139%	-76%	-272%	-208%
Shares Outstanding (Diluted)	96.05	89.92	84.35	79.22	77.7	80.4
Shares Change (YoY)	12%	7%	6%	2%	-3%	22%
EPS (Diluted)	-5.91	-6.46	-4.34	-1.93	-8.36	4.7
EPS Growth	32%	49%	124%	-77%	-278%	-189%
Free Cash Flow	-426	-370	-144	-272	-532	457
Free Cash Flow Per Share	-4.43	-4.11	-1.7	-3.43	-6.84	5.68
Gross Margin	--	--	--	--	--	--
Operating Margin	-16,150%	-18,933.33%	-1,259.45%	-59.83%	-67,300%	40.76%
Profit Margin	-14,200%	-19,366.66%	-989.18%	-41.23%	-65,000%	41.2%
Free Cash Flow Margin	-10,650%	-12,333.33%	-389.18%	-73.31%	-53,200%	49.94%
EBITDA	-627	-549	-447	-203	-649	391
EBITDA Margin	-15,675%	-18,300%	-1,208.1%	-54.71%	-64,900%	42.73%
D&A For EBITDA	19	19	19	19	24	18
EBIT	-646	-568	-466	-222	-673	373
EBIT Margin	-16,150%	-18,933.33%	-1,259.45%	-59.83%	-67,300%	40.76%
Effective Tax Rate	-0.53%	-0.51%	-0.82%	-1.33%	0%	0.26%

CRISPR Therapeutics AG (CRSP) Price

CRSP Stock Price Chart

CRSP Income

Follow-Up Questions